Cargando…

The economic impact of comorbidity in multiple sclerosis

BACKGROUND: Comorbid conditions are common in people with multiple sclerosis (pwMS). They can delay diagnosis and negatively impact the disease course, progression of disability, therapeutic management, and adherence to treatment. OBJECTIVE: To quantify the economic impact of comorbidity in multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponzio, Michela, Monti, Maria Cristina, Mallucci, Giulia, Borrelli, Paola, Fusco, Sara, Tacchino, Andrea, Brichetto, Giampaolo, Tronconi, Livio, Montomoli, Cristina, Bergamaschi, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925507/
https://www.ncbi.nlm.nih.gov/pubmed/36441342
http://dx.doi.org/10.1007/s10072-022-06517-7
_version_ 1784888078339407872
author Ponzio, Michela
Monti, Maria Cristina
Mallucci, Giulia
Borrelli, Paola
Fusco, Sara
Tacchino, Andrea
Brichetto, Giampaolo
Tronconi, Livio
Montomoli, Cristina
Bergamaschi, Roberto
author_facet Ponzio, Michela
Monti, Maria Cristina
Mallucci, Giulia
Borrelli, Paola
Fusco, Sara
Tacchino, Andrea
Brichetto, Giampaolo
Tronconi, Livio
Montomoli, Cristina
Bergamaschi, Roberto
author_sort Ponzio, Michela
collection PubMed
description BACKGROUND: Comorbid conditions are common in people with multiple sclerosis (pwMS). They can delay diagnosis and negatively impact the disease course, progression of disability, therapeutic management, and adherence to treatment. OBJECTIVE: To quantify the economic impact of comorbidity in multiple sclerosis (MS), based on cost-of-illness estimates made using a bottom-up approach. METHODS: A retrospective study was carried out in two northern Italian areas. The socio-demographic and clinical information, including comorbidities data, were collected through ad hoc anonymous self-assessment questionnaire while disease costs (direct and indirect costs of disease and loss of productivity) were estimated using a bottom-up approach. Costs were compared between pwMS with and without comorbidity. Adjusted incremental costs associated with comorbidity were reported using generalized linear models with log-link and gamma distributions or two-part models. RESULTS: 51.0% of pwMS had at least one comorbid condition. Hypertension (21.0%), depression (15.7%), and anxiety (11.7%) were the most prevalent. PwMS with comorbidity were more likely to use healthcare resources, such as hospitalizations (OR = 1.21, p < 0.001), tests (OR = 1.59, p < 0.001), and symptomatic drugs and supplements (OR = 1.89, p = 0.012), and to incur non-healthcare costs related to investment (OR = 1.32, p < 0.001), transportation (OR = 1.33, p < 0.001), services (OR = 1.33, p < 0.001), and informal care (OR = 1.43, p = 0.16). Finally, they experienced greater productivity losses (OR = 1.34, p < 0.001) than pwMS without comorbidity. The adjusted incremental annual cost per patient due to comorbidity was €3,106.9 (13% of the overall costs) with MS disability found to exponentially affect annual costs. CONCLUSION: Comorbidity has health, social, and economic consequences for pwMS.
format Online
Article
Text
id pubmed-9925507
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-99255072023-02-15 The economic impact of comorbidity in multiple sclerosis Ponzio, Michela Monti, Maria Cristina Mallucci, Giulia Borrelli, Paola Fusco, Sara Tacchino, Andrea Brichetto, Giampaolo Tronconi, Livio Montomoli, Cristina Bergamaschi, Roberto Neurol Sci Original Article BACKGROUND: Comorbid conditions are common in people with multiple sclerosis (pwMS). They can delay diagnosis and negatively impact the disease course, progression of disability, therapeutic management, and adherence to treatment. OBJECTIVE: To quantify the economic impact of comorbidity in multiple sclerosis (MS), based on cost-of-illness estimates made using a bottom-up approach. METHODS: A retrospective study was carried out in two northern Italian areas. The socio-demographic and clinical information, including comorbidities data, were collected through ad hoc anonymous self-assessment questionnaire while disease costs (direct and indirect costs of disease and loss of productivity) were estimated using a bottom-up approach. Costs were compared between pwMS with and without comorbidity. Adjusted incremental costs associated with comorbidity were reported using generalized linear models with log-link and gamma distributions or two-part models. RESULTS: 51.0% of pwMS had at least one comorbid condition. Hypertension (21.0%), depression (15.7%), and anxiety (11.7%) were the most prevalent. PwMS with comorbidity were more likely to use healthcare resources, such as hospitalizations (OR = 1.21, p < 0.001), tests (OR = 1.59, p < 0.001), and symptomatic drugs and supplements (OR = 1.89, p = 0.012), and to incur non-healthcare costs related to investment (OR = 1.32, p < 0.001), transportation (OR = 1.33, p < 0.001), services (OR = 1.33, p < 0.001), and informal care (OR = 1.43, p = 0.16). Finally, they experienced greater productivity losses (OR = 1.34, p < 0.001) than pwMS without comorbidity. The adjusted incremental annual cost per patient due to comorbidity was €3,106.9 (13% of the overall costs) with MS disability found to exponentially affect annual costs. CONCLUSION: Comorbidity has health, social, and economic consequences for pwMS. Springer International Publishing 2022-11-28 2023 /pmc/articles/PMC9925507/ /pubmed/36441342 http://dx.doi.org/10.1007/s10072-022-06517-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Ponzio, Michela
Monti, Maria Cristina
Mallucci, Giulia
Borrelli, Paola
Fusco, Sara
Tacchino, Andrea
Brichetto, Giampaolo
Tronconi, Livio
Montomoli, Cristina
Bergamaschi, Roberto
The economic impact of comorbidity in multiple sclerosis
title The economic impact of comorbidity in multiple sclerosis
title_full The economic impact of comorbidity in multiple sclerosis
title_fullStr The economic impact of comorbidity in multiple sclerosis
title_full_unstemmed The economic impact of comorbidity in multiple sclerosis
title_short The economic impact of comorbidity in multiple sclerosis
title_sort economic impact of comorbidity in multiple sclerosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925507/
https://www.ncbi.nlm.nih.gov/pubmed/36441342
http://dx.doi.org/10.1007/s10072-022-06517-7
work_keys_str_mv AT ponziomichela theeconomicimpactofcomorbidityinmultiplesclerosis
AT montimariacristina theeconomicimpactofcomorbidityinmultiplesclerosis
AT malluccigiulia theeconomicimpactofcomorbidityinmultiplesclerosis
AT borrellipaola theeconomicimpactofcomorbidityinmultiplesclerosis
AT fuscosara theeconomicimpactofcomorbidityinmultiplesclerosis
AT tacchinoandrea theeconomicimpactofcomorbidityinmultiplesclerosis
AT brichettogiampaolo theeconomicimpactofcomorbidityinmultiplesclerosis
AT tronconilivio theeconomicimpactofcomorbidityinmultiplesclerosis
AT montomolicristina theeconomicimpactofcomorbidityinmultiplesclerosis
AT bergamaschiroberto theeconomicimpactofcomorbidityinmultiplesclerosis
AT ponziomichela economicimpactofcomorbidityinmultiplesclerosis
AT montimariacristina economicimpactofcomorbidityinmultiplesclerosis
AT malluccigiulia economicimpactofcomorbidityinmultiplesclerosis
AT borrellipaola economicimpactofcomorbidityinmultiplesclerosis
AT fuscosara economicimpactofcomorbidityinmultiplesclerosis
AT tacchinoandrea economicimpactofcomorbidityinmultiplesclerosis
AT brichettogiampaolo economicimpactofcomorbidityinmultiplesclerosis
AT tronconilivio economicimpactofcomorbidityinmultiplesclerosis
AT montomolicristina economicimpactofcomorbidityinmultiplesclerosis
AT bergamaschiroberto economicimpactofcomorbidityinmultiplesclerosis